Fig. 3
Median and 25th and 75th percentile LDLC (mg/dl) at study entry and 4, 12, and 24 weeks follow-up on Evolocumab 140 mg every two weeks
Fig. 3 | Lipids in Health and Disease
Median and 25th and 75th percentile LDLC (mg/dl) at study entry and 4, 12, and 24 weeks follow-up on Evolocumab 140 mg every two weeks
Lipids in Health and Disease